ipharmaservicesFeb 21Novartis’ blockbuster Entresto received the US FDA approval for a broader target populationNovartis has received the US FDA approval of Entresto ((sacubitril/valsartan) for the broader target population; it is now approved for p...
ipharmaservicesJan 20Merck and Bayer announced the US FDA approval for Verquvo Merck and Bayer have announced that the companies have received the US FDA's approval for Verquvo (vericiguat). The drug is approved for ...
ipharmaservicesJan 12Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio
ipharmaservicesJan 12Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patientsBiogen has announced that the first patient with spinal muscular atrophy (SMA) has been treated with Spinraza (nusinersen), who were prio...
ipharmaservicesJan 5Lynparza was approved for three more indications in JapanAstraZeneca and Merck announced that Lynparza (olaparib) was approved for three more indications in Japan. The three new cancer indicatio...
ipharmaservicesDec 28, 2020Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphomaKite announced that it received conditional approval in Europe for Tecartus (brexucabtagene autoleucel). Tecartus is a chimeric antigen r...
ipharmaservicesDec 26, 2020Novartis plans to strengthen its neurology portfolio with the acquisition of Cadent TherapeuticsNovartis entered an agreement to acquire Cadent Therapeutics. Cadent Therapeutics was launched by merging Luc Therapeutics and Ataxion Th...
ipharmaservicesOct 17, 2020REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS
ipharmaservicesOct 9, 2020European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine
ipharmaservicesOct 3, 2020HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety
